Daniel M Harrison1, Snehashis Roy2, Jiwon Oh3, Izlem Izbudak4, Dzung Pham2, Susan Courtney5, Brian Caffo6, Craig K Jones7, Peter van Zijl7, Peter A Calabresi8. 1. Department of Neurology, School of Medicine, University of Maryland, Baltimore2Department of Neurology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland. 2. Center for Neuroscience and Regenerative Medicine, Henry Jackson Foundation, Bethesda, Maryland. 3. Department of Neurology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland4Department of Neurology, University of Toronto, Toronto, Ontario, Canada. 4. Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, Maryland. 5. Department of Psychological and Brain Sciences, The Johns Hopkins University, Baltimore, Maryland. 6. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 7. Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, Maryland8F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland. 8. Department of Neurology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland.
Abstract
IMPORTANCE: Cortical lesions (CLs) contribute to physical and cognitive disability in multiple sclerosis (MS). Accurate methods for visualization of CLs are necessary for future clinical studies and therapeutic trials in MS. OBJECTIVE: To evaluate the clinical relevance of measures of CL burden derived from high-field magnetic resonance imaging (MRI) in MS. DESIGN, SETTING, AND PARTICIPANTS: An observational clinical imaging study was conducted at an academic MS center. Participants included 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive) and 15 healthy individuals serving as controls. The study was conducted from March 10, 2010, to November 23, 2012, and analysis was performed from June 1, 2011, to September 30, 2014. Seven-Tesla MRI of the brain was performed with 0.5-mm isotropic resolution magnetization-prepared rapid acquisition gradient echo (MPRAGE) and whole-brain, 3-dimensional, 1.0-mm isotropic resolution magnetization-prepared, fluid-attenuated inversion recovery (MPFLAIR). Cortical lesions, seen as hypointensities on MPRAGE, were manually segmented. Lesions were classified as leukocortical, intracortical, or subpial. Images were segmented using the Lesion-TOADS (Topology-Preserving Anatomical Segmentation) algorithm, and brain structure volumes and white matter (WM) lesion volume were reported. Volumes were normalized to intracranial volume. MAIN OUTCOMES AND MEASURES: Physical disability was measured by the Expanded Disability Status Scale (EDSS). Cognitive disability was measured with the Minimal Assessment of Cognitive Function in MS battery. RESULTS: Cortical lesions were noted in 35 of 36 participants (97%), with a median of 16 lesions per participant (range, 0-99). Leukocortical lesion volume correlated with WM lesion volume (ρ = 0.50; P = .003) but not with cortical volume; subpial lesion volume inversely correlated with cortical volume (ρ = -0.36; P = .04) but not with WM lesion volume. Total CL count and volume, measured as median (range), were significantly increased in participants with EDSS scores of 5.0 or more vs those with scores less than 5.0 (count: 29 [11-99] vs 13 [0-51]; volume: 2.81 × 10-4 [1.30 × 10-4 to 7.90 × 10-4] vs 1.50 × 10-4 [0 to 1.01 × 10-3]) and in cognitively impaired vs unimpaired individuals (count: 21 [0-99] vs 13 [1-54]; volume: 3.51 × 10-4 [0 to 1.01 × 10-4] vs 1.19 × 10-4 [0 to 7.17 × 10-4]). Cortical lesion volume correlated with EDSS scores more robustly than did WM lesion volume (ρ = 0.59 vs 0.36). Increasing log[CL volume] conferred a 3-fold increase in the odds of cognitive impairment (odds ratio [OR], 3.36; 95% CI, 1.07-10.59; P = .04) after adjustment for age and sex and a 14-fold increase in odds after adjustment for WM lesion volume and atrophy (OR, 14.26; 95% CI, 1.06-192.37; P = .045). Leukocortical lesions had the greatest effect on cognition (OR for log [leukocortical lesion volume], 9.65; 95% CI, 1.70-54.59, P = .01). CONCLUSIONS AND RELEVANCE: This study provides in vivo evidence that CLs are associated with cognitive and physical disability in MS and that leukocortical and subpial lesion subtypes have differing clinical relevance. Quantitative assessments of CL burden on high-field MRI may further our understanding of the development of disability and progression in MS and lead to more effective treatments.
IMPORTANCE: Cortical lesions (CLs) contribute to physical and cognitive disability in multiple sclerosis (MS). Accurate methods for visualization of CLs are necessary for future clinical studies and therapeutic trials in MS. OBJECTIVE: To evaluate the clinical relevance of measures of CL burden derived from high-field magnetic resonance imaging (MRI) in MS. DESIGN, SETTING, AND PARTICIPANTS: An observational clinical imaging study was conducted at an academic MS center. Participants included 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive) and 15 healthy individuals serving as controls. The study was conducted from March 10, 2010, to November 23, 2012, and analysis was performed from June 1, 2011, to September 30, 2014. Seven-Tesla MRI of the brain was performed with 0.5-mm isotropic resolution magnetization-prepared rapid acquisition gradient echo (MPRAGE) and whole-brain, 3-dimensional, 1.0-mm isotropic resolution magnetization-prepared, fluid-attenuated inversion recovery (MPFLAIR). Cortical lesions, seen as hypointensities on MPRAGE, were manually segmented. Lesions were classified as leukocortical, intracortical, or subpial. Images were segmented using the Lesion-TOADS (Topology-Preserving Anatomical Segmentation) algorithm, and brain structure volumes and white matter (WM) lesion volume were reported. Volumes were normalized to intracranial volume. MAIN OUTCOMES AND MEASURES: Physical disability was measured by the Expanded Disability Status Scale (EDSS). Cognitive disability was measured with the Minimal Assessment of Cognitive Function in MS battery. RESULTS:Cortical lesions were noted in 35 of 36 participants (97%), with a median of 16 lesions per participant (range, 0-99). Leukocortical lesion volume correlated with WM lesion volume (ρ = 0.50; P = .003) but not with cortical volume; subpial lesion volume inversely correlated with cortical volume (ρ = -0.36; P = .04) but not with WM lesion volume. Total CL count and volume, measured as median (range), were significantly increased in participants with EDSS scores of 5.0 or more vs those with scores less than 5.0 (count: 29 [11-99] vs 13 [0-51]; volume: 2.81 × 10-4 [1.30 × 10-4 to 7.90 × 10-4] vs 1.50 × 10-4 [0 to 1.01 × 10-3]) and in cognitively impaired vs unimpaired individuals (count: 21 [0-99] vs 13 [1-54]; volume: 3.51 × 10-4 [0 to 1.01 × 10-4] vs 1.19 × 10-4 [0 to 7.17 × 10-4]). Cortical lesion volume correlated with EDSS scores more robustly than did WM lesion volume (ρ = 0.59 vs 0.36). Increasing log[CL volume] conferred a 3-fold increase in the odds of cognitive impairment (odds ratio [OR], 3.36; 95% CI, 1.07-10.59; P = .04) after adjustment for age and sex and a 14-fold increase in odds after adjustment for WM lesion volume and atrophy (OR, 14.26; 95% CI, 1.06-192.37; P = .045). Leukocortical lesions had the greatest effect on cognition (OR for log [leukocortical lesion volume], 9.65; 95% CI, 1.70-54.59, P = .01). CONCLUSIONS AND RELEVANCE: This study provides in vivo evidence that CLs are associated with cognitive and physical disability in MS and that leukocortical and subpial lesion subtypes have differing clinical relevance. Quantitative assessments of CL burden on high-field MRI may further our understanding of the development of disability and progression in MS and lead to more effective treatments.
Authors: David Pitt; Aaron Boster; Wei Pei; Eric Wohleb; Adam Jasne; Cherian R Zachariah; Kottil Rammohan; Michael V Knopp; Petra Schmalbrock Journal: Arch Neurol Date: 2010-07
Authors: Varun Sethi; Tarek A Yousry; Nils Muhlert; Maria Ron; Xavier Golay; Claudia Wheeler-Kingshott; David H Miller; Declan T Chard Journal: J Neurol Neurosurg Psychiatry Date: 2012-07-17 Impact factor: 10.154
Authors: Megan Walsh; Caroline A Montojo; Yi-Shin Sheu; Steven A Marchette; Daniel M Harrison; Scott D Newsome; Feng Zhou; Amy L Shelton; Susan M Courtney Journal: Brain Connect Date: 2011
Authors: M Calabrese; V Bernardi; M Atzori; I Mattisi; A Favaretto; F Rinaldi; P Perini; P Gallo Journal: Mult Scler Date: 2011-01-12 Impact factor: 6.312
Authors: Hanneke E Hulst; Martijn D Steenwijk; Adriaan Versteeg; Petra J W Pouwels; Hugo Vrenken; Bernard M J Uitdehaag; Chris H Polman; Jeroen J G Geurts; Frederik Barkhof Journal: Neurology Date: 2013-03-06 Impact factor: 9.910
Authors: Tim Sinnecker; Jan Dörr; Caspar F Pfueller; Lutz Harms; Klemens Ruprecht; Sven Jarius; Wolfgang Brück; Thoralf Niendorf; Jens Wuerfel; Friedemann Paul Journal: Neurology Date: 2012-08-01 Impact factor: 9.910
Authors: Wolter L de Graaf; Jaco J M Zwanenburg; Fredy Visser; Mike P Wattjes; Petra J W Pouwels; Jeroen J G Geurts; Chris H Polman; Frederik Barkhof; Peter R Luijten; Jonas A Castelijns Journal: Eur Radiol Date: 2011-08-27 Impact factor: 5.315
Authors: Varun Sethi; Nils Muhlert; Maria Ron; Xavier Golay; Claudia A Wheeler-Kingshott; David H Miller; Declan T Chard; Tarek A Yousry Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: Burcu Zeydan; Val J Lowe; Christopher G Schwarz; Scott A Przybelski; Nirubol Tosakulwong; Samantha M Zuk; Matthew L Senjem; Jeffrey L Gunter; Rosebud O Roberts; Michelle M Mielke; Eduardo E Benarroch; Moses Rodriguez; Mary M Machulda; Timothy G Lesnick; David S Knopman; Ronald C Petersen; Clifford R Jack; Kejal Kantarci; Orhun H Kantarci Journal: Mult Scler Date: 2017-05-05 Impact factor: 6.312
Authors: Constantina A Treaba; Elena Herranz; Valeria T Barletta; Ambica Mehndiratta; Russell Ouellette; Jacob A Sloane; Eric C Klawiter; Revere P Kinkel; Caterina Mainero Journal: J Neurol Date: 2021-02-01 Impact factor: 4.849
Authors: E S Beck; P Sati; V Sethi; T Kober; B Dewey; P Bhargava; G Nair; I C Cortese; D S Reich Journal: AJNR Am J Neuroradiol Date: 2018-02-08 Impact factor: 3.825
Authors: Mehrnaz Ighani; Samuel Jonas; Izlem Izbudak; Seongjin Choi; Alfonso Lema-Dopico; Jun Hua; Erin E O'Connor; Daniel M Harrison Journal: Mult Scler Date: 2019-10-01 Impact factor: 6.312
Authors: Phillip DiGiacomo; Julian Maclaren; Murat Aksoy; Elizabeth Tong; Mackenzie Carlson; Bryan Lanzman; Syed Hashmi; Ronald Watkins; Jarrett Rosenberg; Brian Burns; Timothy W Skloss; Dan Rettmann; Brian Rutt; Roland Bammer; Michael Zeineh Journal: Magn Reson Med Date: 2020-02-20 Impact factor: 4.668
Authors: Augustin Lecler; C Bouzad; R Deschamps; F Maizeroi; J C Sadik; A Gueguen; O Gout; H Picard; J Savatovsky Journal: J Neurol Date: 2019-08-01 Impact factor: 4.849